A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

摘要: BACKGROUND Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase effectiveness and safety acenocoumarol phenprocoumon therapy. METHODS We conducted two single-blind, randomized trials comparing included clinical variables genotyping for CYP2C9 VKORC1 with only variables, initiation or treatment in patients atrial fibrillation venous thromboembolism. The primary outcome was percentage time target range international normalized ratio (INR; range, 2.0 to 3.0) 12-week period after Owing low enrollment, were combined analysis. assessed who remained trial at least 10 weeks. RESULTS A total 548 enrolled (273 group 275 control group). follow-up weeks 239 245 group. therapeutic INR 61.6% receiving 60.2% those clinically guided (P = 0.52). There no significant differences between groups several secondary outcomes. during first 4 52.8% 47.5% 0.02), respectively. respect incidence bleeding thromboembolic events. CONCLUSIONS Genotype-guided did not improve 12 (Funded by European Commission Seventh Framework Programme others; EU-PACT ClinicalTrials.gov numbers, NCT01119261 NCT01119274.)